that change the game!
new/era/mabs redefines antibody discovery
what's in it for you?
new/era/mabs GmbH is a privately financed biotech company with a proprietary technology platform for the generation of monoclonal and recombinant antibodies for use in research, diagnostic and therapeutic applications.
We provide high-end antibody discovery workflows four times faster than conventional state-of-the-art processes. The platform core component is selma - a highly flexible selection process for antibody-producing cells based on novel transgenic fusion cell lines.
We offer the customized generation and production of mouse, camelid, and human antibodies for various in vitro and in vivo applications. We permanently expand our R&D segment with next-generation platform add-ons and hold all intellectual property rights as different patent families.
Founded in 2014 as an university spin-off located at the Potsdam Science Park the company is embedded in a vibrant scientific environment.
Are you ready to enter a new era of antibody generation?get in touch
our groundbreaking technology
Antibodies are wonderful and reliable tools but the generation so far is tedious and resource intensive. Selecting suitable antibodies is highly complex. When using selma as selection tool you can absolutely rely on having a fast, efficient and highly flexible technology to select your desired antibody producing cell.learn more
murine monoclonal antibodies
The induction of specific antibody responses in mice is performed by immunizing with the antigen of choice. To increase the efficacy of this process we developed a hyper-immunization protocol based on viral carrier proteins. In combination with selma as selection tool we provide a high end solution for the discovery of antibody producing hybridoma cells four times faster than with conventional methods.learn more
human monoclonal antibodies
We use a fast and reliable workflow for human monoclonal antibodies, too. Human B cells are specifically activated by our proprietary in vitro immunization (IVI). Either customized antigens or our virus-derived antigen carriers are used for the antigen-specific immunization. And, how would you select the desired antibody-producing cells? You are absolutely right if your answer is - selma!learn more
camelid recombinant antibodies
Camelid antibodies were recently spotlighted due to their exclusive properties such as a high temperature stability which would allow workflows without needing a cool chain. This is a very interesting feature for in vitro diagnostic applications. We carry out the generation of either variable heavy chain antibody fragments (15 kDa) or full length heavy chain only antibodies (90 kDa) for the establishment of a specific test environment. We either use our proprietary naïve camelid antibody library or individually created custom immune libraries for identification. Again, antibody-producing mammalian cells are selected with selma.learn more
published in nature
A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line.read article
published in Science
In this Science webinar, Katja Hanack demonstrates how
significantly simplifies and accelerates antibody characterization by flow cytometry.
After a free registration you can start the recording at 23:17 min.view webinar